Cardialen Raises $17M in Venture Capital to Commercialize Therapy Developed in BME Lab

[et_pb_section fb_built="1" admin_label="section" _builder_version="3.0.47"][et_pb_row admin_label="row" _builder_version="3.0.48" background_size="initial" background_position="top_left" background_repeat="repeat"][et_pb_column type="4_4" _builder_version="3.0.47" parallax="off" parallax_method="on"][et_pb_text _builder_version="3.18.8"]

Cardialen, a company founded by Dr. Igor Efimov has raised $17 million in Series B funding from venture capital.  Dr. Efimov’s lab has developed a way to defibrillate the heart with a technique that uses a precisely timed series of low-voltage pulses, rather than one big shock, to reset the heart’s electric system.  Cardialen is working to commercialize the therapy.  The venture funding was mentioned in an October 10 article in The Minneapolis Star-Tribune, “Minneapolis startup Cardialen raises $17 million in venture capital.”

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]